Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castrate Resistance Prostate Cancer”

286 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 286 results

Not applicableStudy completedNCT02353715
What this trial is testing

Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

Who this might be right for
Prostate Cancer
Duke University 38
Testing effectiveness (Phase 2)Study completedNCT01942837
What this trial is testing

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute 67
Testing effectiveness (Phase 2)Ended earlyNCT01313559
What this trial is testing

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Who this might be right for
Castrate Resistant Prostate CancerChemotherapy Naive Prostate CancerProstate Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 6
Early research (Phase 1)Ended earlyNCT02500901
What this trial is testing

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Prostate Cancer
Paul Mathew, MD 2
Early research (Phase 1)Study completedNCT00868595
What this trial is testing

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Who this might be right for
Castrate Resistant Prostate Cancer (CRPC)
Bellicum Pharmaceuticals 18
Testing effectiveness (Phase 2)Study completedNCT00849121
What this trial is testing

Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
University of Wisconsin, Madison 17
Testing effectiveness (Phase 2)Study completedNCT01511536
What this trial is testing

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Sanofi 38
Testing effectiveness (Phase 2)Study completedNCT01051570
What this trial is testing

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Who this might be right for
Prostate Cancer
Barbara Ann Karmanos Cancer Institute 26
Early research (Phase 1)Study completedNCT02259114
What this trial is testing

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Who this might be right for
NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation+3 more
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47
Early research (Phase 1)Ended earlyNCT05037500
What this trial is testing

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8+1 more
Roswell Park Cancer Institute 8
Testing effectiveness (Phase 2)Ended earlyNCT04631744
What this trial is testing

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 4
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96
Not applicableStudy completedNCT01961843
What this trial is testing

Abiraterone Acetate for Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Massachusetts General Hospital 40
Early research (Phase 1)Study completedNCT02740985
What this trial is testing

Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid MalignanciesNon-Small Cell Lung Cancer (NSCLC)Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)+1 more
AstraZeneca 313
Testing effectiveness (Phase 2)Looking for participantsNCT06610825
What this trial is testing

Castrate Resistant Prostate Cancer Enhertu Therapy

Who this might be right for
Prostate Cancer MetastaticProstate CancerCRPC
Washington D.C. Veterans Affairs Medical Center 60
Not applicableEnded earlyNCT04436120
What this trial is testing

Treatment Resistance Following Anti-cancer Therapies

Who this might be right for
Disease Progression
Pfizer 38
Testing effectiveness (Phase 2)Study completedNCT01393730
What this trial is testing

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Mary-Ellen Taplin, MD 40
Early research (Phase 1)Study completedNCT04148937
What this trial is testing

The CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 52
Early research (Phase 1)Study completedNCT01884285
What this trial is testing

AZD8186 First Time In Patient Ascending Dose Study

Who this might be right for
Advanced Castrate-resistant Prostate Cancer CRPCSquamous Non-Small Cell Lung Cancer sqNSCLCTriple Negative Breast Cancer TNBC
AstraZeneca 147
Testing effectiveness (Phase 2)Ended earlyNCT02607228
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer
Gilead Sciences 31
Next Page